A carregar...
CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway
BACKGROUND: Cisplatin (DDP) is standard-of-care and first-line management for ovarian cancer (OvCa). Circular RNA HIPK2 (circHIPK2) is abnormally upregulated in serum of OvCa patients. However, its role in DDP resistance remains unclear. METHODS: Expression of cirHIPK2, microRNA (miR)-338-3p and chr...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8128508/ https://ncbi.nlm.nih.gov/pubmed/34012271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S291823 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|